Prediction of drugs having opposite effects on disease genes in a directed network
暂无分享,去创建一个
Junseok Park | Sungji Choo | Doheon Lee | Yeeok Kang | Hasun Yu | Jinmyung Jung | Doheon Lee | Junseok Park | J. Jung | Hasun Yu | Sungji Choo | Yeeok Kang
[1] T. Tatusova,et al. Entrez Gene: gene-centered information at NCBI , 2010, Nucleic Acids Res..
[2] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[3] Jun Zou,et al. Neighbor communities in drug combination networks characterize synergistic effect. , 2012, Molecular bioSystems.
[4] T. Hogan,et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib , 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[5] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[6] J. Davis. Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .
[7] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[8] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[9] Antoine H. C. van Kampen,et al. Consensus and conflict cards for metabolic pathway databases , 2013, BMC Systems Biology.
[10] Yuhao Wang,et al. Predicting drug-target interactions using restricted Boltzmann machines , 2013, Bioinform..
[11] Bo Zhang,et al. Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.
[12] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[13] Fiorenza Gianì,et al. Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. , 2013, The Journal of clinical endocrinology and metabolism.
[14] Michiaki Mishima,et al. Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Stimson P. Schantz,et al. Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer , 2011, PloS one.
[16] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[17] Carlos Matute,et al. Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.
[18] Sungji Choo,et al. Context-based resolution of semantic conflicts in biological pathways , 2015, BMC Medical Informatics and Decision Making.
[19] H. Lowe,et al. Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches. , 1994, JAMA.
[20] Yutaka Yamamoto,et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells , 2006, Cancer Chemotherapy and Pharmacology.
[21] Mohammed Al-Shalalfa,et al. Prediction of novel drug indications using network driven biological data prioritization and integration , 2014, Journal of Cheminformatics.
[22] Guanghui Hu,et al. Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.
[23] Thomas C. Wiegers,et al. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical–gene–disease networks , 2008, Nucleic Acids Res..
[24] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[25] M. Landriscina,et al. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. , 2010, Anticancer research.
[26] Thomas J Lynch,et al. A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.
[27] Stefan Wiemann,et al. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor , 2009, Bioinform..
[28] Naomi Luxford,et al. Integrated decision-making about housing, energy and wellbeing: a qualitative system dynamics model , 2016, Environmental Health.
[29] Alexander E. Ivliev,et al. Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.
[30] Helen Y Wang,et al. Cell type-specific function of TAK1 in innate immune signaling. , 2013, Trends in immunology.
[31] Y. Fukuoka,et al. A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs , 2013, Bioinformation.
[32] Xiang Zhang,et al. Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..
[33] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[34] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[35] Mickael Guedj,et al. Should We Abandon the t-Test in the Analysis of Gene Expression Microarray Data: A Comparison of Variance Modeling Strategies , 2010, PloS one.
[36] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[37] B Nebiyou Bekele,et al. Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice , 2006, Clinical Cancer Research.
[38] Mahitosh Mandal,et al. Concurrent Cetuximab and Bevacizumab Therapy in a Murine Orthotopic Model of Anaplastic Thyroid Carcinoma , 2007, The Laryngoscope.
[39] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[40] Michael Hay,et al. Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.
[41] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..